Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Raynaud, C.; Greillier, L.; Mazieres, J.; Monnet, I.; Mastroianni, B.; Robinet, G.; Fraboulet, G.; Dixmier, A.; Berard, H.; Lamy, R.; Letreut, J.; Lena, H.; Oliviero, G.; Botta, S.; Vergnenegre, A.; Borget, I.; Chouaid, C.
• Is Part Of: BMC cancer. Volume 15:Issue 1(2015)
• Page Start: 1
• Page End: 6
• Publication Date: 2015-12
• Subjects: Malignant pleural mesothelioma -- Treatment -- Chemotherapy; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-015-1881-x
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients' profiles and management in daily practice in France. Methods Observational retrospective study. Data were collected from medical files. All patients with histologically proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites. Results Four hundred and six patients were included in 37 sites: mean age 68.9 ± 9.8 years, male predominance (sex ratio 3.27), latency of the disease 45.7 years, epithelioïd type 83 %. Diagnosis was made using thoracoscopy in 80.8 % of patients. Radical surgery was performed in 6.2 % of cases. Chemotherapy was administered to 74.6 % of patients. First line regimens consisted mainly of platinum + pemetrexed (91 %) or pemetrexed alone (7 %). Objective response rate was 17.2 % and another 41.6 % of patients experienced disease stabilization. Half of these patients underwent second line chemotherapy (platinium + pemetrexed 31.6 %, pemetrexed alone 24.6 %), resulting in a 6 % response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4 % of cases. Conclusions The management of MPM in France is usually in accordance with guidelines. Response rates are somewhat lower than those described in clinical trials.